This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-08 and is reviewed periodically as new material appears.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Michel Gondry was working on a film adaptation in early 2011, with Steve Golin and Steve Zaillian producing. In 2014, however, Gondry told French outlet Telerama (via Jeux Actu) that he was no longer working on the project and explained: "The book is brilliant, but it's good as a literary work. Having tried to adapt it with several screenwriters, ... at the moment I don't feel up to doing it. It doesn't have the dramatic structure that would make it a good film. I received a script that disheartened me a bit, and that was it. It was a dream, but in life you can't always have what you want."
==== United Kingdom ==== Cannabidiol, in an oral-mucosal spray formulation combined with delta-9-tetrahydrocannabinol, is a product available by prescription for the relief of severe spasticity due to multiple sclerosis (where other anti-spasmodics have not been effective) in the United Kingdom. Until 2017, products containing cannabidiol marketed for medical purposes were classed as medicines by the UK regulatory body, the Medicines and Healthcare products Regulatory Agency (MHRA), and could not be marketed without regulatory approval for the medical claims. As of 2018, cannabis oil is legal to possess, buy, and sell in the UK, providing the product does not contain more than 1 milligram of THC and is not advertised as providing a medicinal benefit. Individual police officers and others who are ill-informed of the exact legislature pertaining to cannabidiol, however, may erroneously consider it of dubious legality, reflecting lack of awareness. In January 2019, the UK Food Standards Agency indicated it would regard CBD products, including CBD oil, as a novel food having no history of use before May 1997, and stated that such products must have authorisation and proven safety before being marketed. The deadline for companies with existing products to submit a full and validated novel foods application with the FSA was March 31, 2021; failure to do so before this date would exclude those companies from selling CBD. New products containing CBD after this deadline would require a fully approved application.
== Diagnosis == The center of the cornea shows normal thickness, with an intact central epithelium, but the inferior cornea exhibits a peripheral band of thinning, to about 1–2 mm. The portion of the cornea that is immediately adjacent to the limbus is spared, usually a strip of about 1–2 mm. In PMD we can see high against the rule astigmatism along with horizontal bow ties. The inferior peripheral thinning is seen between the 4 o'clock and 8 o'clock positions. PMD lacks apical corneal scarring, Rizutti's phenomenon, Munson's sign, and the central corneal thickness is usually normal. The gold standard diagnostic test for PMD is corneal topography. However, it may not be as specific as corneal pachymetry, because corneal topography only evaluates the degree and distribution of surface irregularities on the cornea, not the thickness of the cornea. Corneal topography may show a "crab claw-like" appearance, a finding that is seen in both keratoconus and in pellucid marginal degeneration. Thus, if corneal topography is used for diagnosis, it should be in conjunction with clinical findings of peripheral, inferior corneal thinning.
=== Other interventions === A 2024 review found that fecal microbiota transplantation may reduce pain intensity and improve fatigue and quality of life in patients with fibromyalgia, but evidence was insufficient at that stage to support use. Research on gut microbiome links with FM continues. Hyperbaric oxygen therapy (HBOT) has shown beneficial effects in treating chronic pain by reducing inflammation and oxidative stress. However, treating fibromyalgia with hyperbaric oxygen therapy is still controversial, in light of the scarcity of large-scale clinical trials. In addition, hyperbaric oxygen therapy raises safety concerns due to the oxidative damage that may follow it. An evaluation of nine trials with 288 patients in total found that HBOT was more effective at relieving fibromyalgia patients' pain than the control intervention. In most of the trials, HBOT improved sleep disturbance, multidimensional function, patient satisfaction, and tender spots. Negative outcomes (predominantly mild barotrauma (air pressure effect on ear or lung) that could be resolved spontaneously) were experienced by 24% of the patients, but they were not prevented from completing the treatment regimen, and no serious side effects, complications, or deaths were reported.
Guanidine is the compound with the formula HNC(NH2)2. It is a colourless solid that dissolves in polar solvents. It is a strong base that is used in the production of plastics and explosives. It is found in urine predominantly in patients experiencing renal failure. A guanidine moiety also appears in larger organic molecules, including on the side chain of arginine.
Sources: en.wikipedia.org
Similar chakra (spoked-wheel) symbols are among the most ancient in all Indian history. Madhavan and Parpola note that a wheel symbol appears frequently in Indus Valley Civilisation artifacts, particularly on several seals. Notably, it is present in a sequence of ten signs on the Dholavira Signboard. Some historians associate the ancient chakra symbols with solar symbolism. In the Vedas, the god Surya is associated with the solar disc, which is said to be a chariot of one wheel (cakra). Mitra, a form of Surya, is described as "the eye of the world", and thus the sun is conceived of as an eye (cakṣu) which illuminates and perceives the world. Such a wheel is also the main attribute of Vishnu. Thus, a wheel symbol might also be associated with light and knowledge.
=== Resistance === Development of bacterial resistance under therapy is a frequent occurrence and makes fosfomycin unsuitable for sustained therapy of severe infections. Mutations that inactivate the nonessential glycerophosphate transporter render bacteria resistant to fosfomycin. Still, fosfomycin can be used to treat MRSA bacteremia. Prescribing fosfomycin together with at least another active drug reduces the risk of developing bacterial resistance. Fosfomycin acts synergistically with many other antibiotics, including aminoglycosides, carbapenems, cephalosporins, daptomycin and oritavancin. Enzymes conferring resistance to fosfomycin have also been identified and are encoded both chromosomally and on plasmids. Three related fosfomycin resistance enzymes (named FosA, FosB, and FosX) are members of the glyoxalase superfamily. These enzymes function by nucleophilic attack on carbon 1 of fosfomycin, which opens the epoxide ring and renders the drug ineffective. The enzymes differ by the identity of the nucleophile used in the reaction: glutathione for FosA, bacillithiol for FosB, and water for FosX. In general, FosA and FosX enzymes are produced by Gram-negative bacteria, whereas FosB is produced by Gram-positive bacteria. FosC uses ATP and adds a phosphate group to fosfomycin, thus altering its properties and making the drug ineffective.
=== Legal status === In December 2016, a new drug application was filed with the US Food and Drug Administration (FDA), and in October 2017, an FDA advisory committee approved it unanimously. In December 2017, the injectable version with the brand name Ozempic was approved in the US for use by people with diabetes, and, in January 2018, in Canada. In February 2018, authorization was granted in the European Union, in March 2018 in Japan, and in August 2019 in Australia. A version of semaglutide to treat diabetes that can be taken orally (Rybelsus) was approved for medical use in the US in September 2019, and in the European Union in April 2020. In January 2023, the US FDA prescription label for Rybelsus was updated to reflect that it can be used as a first-line treatment for adults with type 2 diabetes. In June 2021, a higher-dose version for injectable use, sold under the brand name Wegovy, was approved by the FDA as an anti-obesity medication for long-term weight management in adults. In January 2022, Wegovy was approved for medical use in the European Union. In December 2025, an oral version of semaglutide, sold under the brand name Wegovy, was approved in the US for weight management. In March 2026, the CHMP recommended granting a conditional marketing authorization for Kayshild (semaglutide), a GLP-1 receptor agonist for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis, a serious disease where fat deposits accumulate in the liver causing inflammation.
=== Symmetry breaking === Theories for the origin of homochirality in the molecules of life can be classified as deterministic or based on chance depending on their proposed mechanism. If there is a relationship between cause and effect – that is, a specific chiral field or influence causing the mirror symmetry breaking – the theory is classified as deterministic; otherwise it is classified as a theory based on chance (in the sense of randomness) mechanisms.
Sources: en.wikipedia.org
. Therefore, thicker structures will appear preferentially in forward, and thinner ones in backward: since the SHG conversion depends at first approximation on the square of the number of nonlinear converters, the signal will be higher if emitted by thick structures, thus the signal in forward direction will be higher than in backward. However, the tissue can scatter the generated light, and a part of the SHG in forward can be retro-reflected in the backward direction. Then, the forward-over-backward ratio F/B can be calculated, and is a metric of the global size and arrangement of the SHG converters (usually collagen fibrils). It can also be shown that the higher the out-of-plane angle of the scatterer, the higher its F/B ratio (see fig. 2.14 of ).
== Pathophysiology == Overproduction of collagen is thought to result from an autoimmune dysfunction, in which the immune system starts to attack the kinetochore of the chromosomes. This would lead to genetic malfunction of nearby genes. T cells accumulate in the skin; these are thought to secrete cytokines and other proteins that stimulate collagen deposition. Stimulation of the fibroblast, in particular, seems to be crucial to the disease process, and studies have converged on the potential factors that produce this effect.
Plutonium-244 is one of several extinct radionuclides that preceded the formation of the Solar System. Its half-life of 81.3 million years ensured its circulation across the Solar System before its extinction, and so evidence of it should also be found throughout the Solar System. Radionuclides such as 244Pu, decay to produce fissiogenic (i.e., arising from fission) xenon isotopes that can then be used to time the events of the early Solar System. In fact, by analyzing data from Earth's mantle which indicates that about 30% of existing fissiogenic xenon is from 244Pu decay, it can be inferred that the Earth formed nearly 50–70 million years after the Solar System formed. Before the analysis of mass spectroscopy data from analyzing samples found in meteorites, it was inferential at best to credit 244Pu as being the nuclide responsible for the fissiogenic xenon found. However, an analysis of a laboratory sample of 244Pu compared with that of fissiogenic xenon gathered from the meteorites Pasamonte and Kapoeta produced matching spectra that immediately left little doubt as to the source of the isotopic xenon anomalies. Spectra data was further acquired for another actinide isotope, 244Cm, but such data proved contradictory and helped erase further doubts that the fission was appropriately attributed to 244Pu. Both the examination of spectra data and study of fission tracks led to several findings of plutonium-244. In Western Australia, the analysis of the mass spectrum of xenon in 4.1–4.2-billion-year-old zircons was met with findings of diverse levels of 244Pu fission.
The duplication events provided material for neofunctionalization to create the novel toxin genes, while gene loss influenced speciation and helped lead to such a wide variety of "chemical cocktails" in rattlesnake venoms. The prevailing theory for the driving force of this evolution is directional selection, where efficacy on prey is selected for. Diversity in prey leads to less specificity in toxins, while highly specialized toxins are more likely to develop when there are few key prey species. However, recently, balancing selection has been indicated to better explain the maintenance of adaptive genetic diversity in venom-related genes, potentially allowing for the rattlesnakes to better keep up in the evolutionary arms race with their prey. Older snakes possess more potent venom, and larger snakes are frequently capable of storing larger volumes of it.
Zhang's tactics included propaganda, intelligence-gathering, and involvement in the opium trade, while Liu fought back with counter-propaganda and appointing loyalist magistrates who frustrated Zhang's work. Liu triumphed in 1942 when the 36th Division was moved to the Yunnanese front, and Zhang was transferred back to Chongqing in 1946. Zhang's presence was replaced by He Guoguang, but Liu continued frustrating Nationalist centralization attempts. In 1944 during Operation Ichi-Go, there was once again talk of moving the capital to Xichang, encouraged by American General Wedermeyer, but this was abandoned after the Japanese offensive stalled. In late 1942, Chiang ordered Liu and Ma Bufang of Qinghai to mobilize for a campaign against Tibet. Liu was suspicious of the Nationalist leader's motivations, dispatching his chief of staff Wu Peiying (伍培英) to Chongqing to plan for the invasion and negotiate with Chiang. According to Liu's 1990 biography, he had asked for a fully-equipped division of 10,000 troops, cavalry, and engineers; another division to maintain order, winter equipment, around 10,000 yaks, additional food supplies, and a truck route from Sichuan to Xikang. Liu also requested that he take sole command of these reinforcements. Later archival documents would confirm Liu's suspicions that the campaign was a plot; once Liu had mobilized his forces, Chiang was to send 30,000 men under his personal command into Xikang and depose Liu. Due to Liu's stalling tactics as well as Allied pressure, the campaign did not materialize.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.